ライフサイエンスコーパス: pulmonary fibrosis

1 se to nintedanib in patients with idiopathic pulmonary fibrosis.

2 protected from subsequent bleomycin-induced pulmonary fibrosis.

3 g, Mo-AM differentiation, and development of pulmonary fibrosis.

4 , stop, or reverse progression of idiopathic pulmonary fibrosis.

5 protects from subsequent bleomycin-mediated pulmonary fibrosis.

6 may contribute to its efficacy in combatting pulmonary fibrosis.

7 esence of albinism, platelet dysfunction and pulmonary fibrosis.

8 ysfunction in the pathogenesis of idiopathic pulmonary fibrosis.

9 ncer, but also arthritis, heart diseases, or pulmonary fibrosis.

10 nd 14 COPD loci shared with either asthma or pulmonary fibrosis.

11 , following acute exacerbation of idiopathic pulmonary fibrosis.

12 ted in samples from patients with idiopathic pulmonary fibrosis.

13 e and nintedanib in patients with idiopathic pulmonary fibrosis.

14 fibrotic lungs from patients with idiopathic pulmonary fibrosis.

15 of personalized therapies for patients with pulmonary fibrosis.

16 lusions: We generated a single-cell atlas of pulmonary fibrosis.

17 lung function and slowed the progression of pulmonary fibrosis.

18 l (PBMC) samples of patients with idiopathic pulmonary fibrosis.

19 tial targets for the treatment of idiopathic pulmonary fibrosis.

20 -fibrotic stimuli, which fails in idiopathic pulmonary fibrosis.

21 ic autoinflammatory disease characterized by pulmonary fibrosis.

22 idase inhibitors attenuate bleomycin-induced pulmonary fibrosis.

23 eases including asthma, COPD, and idiopathic pulmonary fibrosis.

24 lung fibrosis but also improves established pulmonary fibrosis.

25 biospy sample from a patient with idiopathic pulmonary fibrosis.

26 for several chronic lung disorders including pulmonary fibrosis.

27 em cells and senescent cells emerging during pulmonary fibrosis.

28 ro and in an adoptive transfer SCID model of pulmonary fibrosis.

29 espiratory failure, secondary infections and pulmonary fibrosis.

30 ng protein, as a cause of autosomal dominant pulmonary fibrosis.

31 inal changes in lungs affected by idiopathic pulmonary fibrosis.

32 may lead to the initiation of silica-induced pulmonary fibrosis.

33 ages and epithelial cells from subjects with pulmonary fibrosis.

34 s and precipitate dyskeratosis congenita and pulmonary fibrosis.

35 tive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.

36 ll population implicated in murine models of pulmonary fibrosis.

37 pecific interstitial pneumonia or idiopathic pulmonary fibrosis.

38 oclonal antibody against CTGF, in idiopathic pulmonary fibrosis.

39 nhibitor CB-839 attenuated bleomycin-induced pulmonary fibrosis.

40 , chronic obstructive pulmonary disease, and pulmonary fibrosis.

41 nts with IPF and mice with bleomycin-induced pulmonary fibrosis.

42 cacy in an animal model of bleomycin-induced pulmonary fibrosis.

43 a promising candidate for in vivo imaging of pulmonary fibrosis.

44 nship with disease progression in idiopathic pulmonary fibrosis.

45 nterstitial lung diseases such as idiopathic pulmonary fibrosis.

46 ostic and prognostic biomarker of idiopathic pulmonary fibrosis.

47 entiviral delivery blunted bleomycin-induced pulmonary fibrosis.

48 at were deficient in MCU were protected from pulmonary fibrosis.

49 in an early stage when there is only little pulmonary fibrosis.

50 he fibrotic changes that underlie idiopathic pulmonary fibrosis.

51 get that when deregulated enables pathogenic pulmonary fibrosis.

52 e been linked to autosomal-dominant familial pulmonary fibrosis.

53 g regeneration in two experimental models of pulmonary fibrosis.

54 nscription factor JUN is highly expressed in pulmonary fibrosis.

55 y offer a promising therapeutic approach for pulmonary fibrosis.

56 ed alongside conventional anti-fibrotics for pulmonary fibrosis.

57 inhibition of glutaminase 1 (GLS1) reverses pulmonary fibrosis.

58 n important cell type in the pathogenesis of pulmonary fibrosis.

59 patients and of mice upon bleomycin-induced pulmonary fibrosis.

60 repair are implicated in the pathogenesis of pulmonary fibrosis.

61 on and secretome of cells from patients with pulmonary fibrosis.

62 were studied in the bleomycin mouse model of pulmonary fibrosis.

63 structive pulmonary disease and interstitial pulmonary fibrosis.

64 basis for the elevation of staphylococci in pulmonary fibrosis.

65 chronic fibroproliferative phase, leading to pulmonary fibrosis.

66 of the lung and drive pathologic scarring in pulmonary fibrosis.

67 s more effective GPCR-targeted therapies for pulmonary fibrosis.

68 safe, and effective treatment for idiopathic pulmonary fibrosis.

69 of nintedanib was progression of idiopathic pulmonary fibrosis (51 [12%] patients continuing ninteda

70 uctive pulmonary disease, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome,

71 Pulmonary fibrosis after asbestos or bleomycin exposure

72 highly vulnerable to infection and developed pulmonary fibrosis after infection.

73 In pulmonary fibrosis, an inflammatory reaction and differe

74 g tissues from both patients with idiopathic pulmonary fibrosis and a mouse model of bleomycin (BLM)-

75 data suggest MARCKS as a druggable target in pulmonary fibrosis and also provide a promising antifibr

76 rgan failure that most commonly manifests as pulmonary fibrosis and are associated with a relatively

77 on and apoptosis are important in idiopathic pulmonary fibrosis and asbestosis.

78 including dyskeratosis congenita, idiopathic pulmonary fibrosis and bone marrow failure.

79 iver disease, non-alcoholic steatohepatitis, pulmonary fibrosis and cancer(4,11).

80 and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer me

81 (miRNAs) was validated in a murine model of pulmonary fibrosis and in IPF tissue samples.

82 Proteins associated with pulmonary fibrosis and inflammation were associated with

83 gen receptor) facilitates the development of pulmonary fibrosis and is mediated in part through micro

84 xposure to silica has been observed to cause pulmonary fibrosis and lung cancer through complex mecha

85 n this study, an experimental mouse model of pulmonary fibrosis and lung samples from patients with I

86 o VEGF-Axxxb, are critical in development of pulmonary fibrosis and may be a paradigm for the regulat

87 transplant donors and eight recipients with pulmonary fibrosis and on one bronchoscopic cryobiospy s

88 nical assessment of patients with idiopathic pulmonary fibrosis and other fibrotic disorders.

89 Patients with idiopathic pulmonary fibrosis and percentage of predicted forced vi

90 In patients with idiopathic pulmonary fibrosis and preserved lung function, treatmen

91 and interstitial lung disease, resulting in pulmonary fibrosis and respiratory failure.

92 human lungs, including those from idiopathic pulmonary fibrosis and scleroderma patients, demonstrate

93 ease progression in patients with idiopathic pulmonary fibrosis and the effect of nintedanib on these

94 sequent inflammatory cascades in propagating pulmonary fibrosis and the extrapulmonary manifestations

95 e of human short telomere syndromes-familial pulmonary fibrosis and uncover nuclear exosome targeting

96 evlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated.

97 , and two-thirds of MDS/AML patients died of pulmonary fibrosis and/or hepatopulmonary syndrome.

98 rders, which include dyskeratosis congenita, pulmonary fibrosis, and aplastic anemia, is characterize

99 ome, inherited retinal disorders, idiopathic pulmonary fibrosis, and Charcot-Marie-Tooth disease, hig

100 ated with alveolar inflammation, measures of pulmonary fibrosis, and disease progression.

101 with several lung diseases, such as asthma, pulmonary fibrosis, and lung cancer (M.

102 disease, heart failure, diabetes, idiopathic pulmonary fibrosis, and scleroderma.

103 c diseases such as severe asthma, idiopathic pulmonary fibrosis, and systemic sclerosis.

104 ty of nintedanib in patients with idiopathic pulmonary fibrosis, and this was analysed in patients wh

105 es, including asthma, acute lung injury, and pulmonary fibrosis, and thus suggest a therapeutic poten

106 Conclusions: Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associate

107 ated genes previously implicated in familial pulmonary fibrosis-as significant contributors to sporad

108 to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 weeks)-for all-cause

109 ts Sixteen participants with SSc (seven with pulmonary fibrosis at high-resolution CT) and 11 healthy

110 we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1,

111 that AECII-specific TERT deficiency enhances pulmonary fibrosis by heightening susceptibility to bleo

112 in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis by micro-CT, evaluating longitudinal

113 to better stratify patients with idiopathic pulmonary fibrosis by risk for lung transplantation allo

114 sis including 262 unrelated individuals with pulmonary fibrosis clinically classified as IPF accordin

115 g tissues and fibroblasts from patients with pulmonary fibrosis compared to controls.

116 cell types in lung tissue from subjects with pulmonary fibrosis compared with control subjects.

117 participants with systemic sclerosis-related pulmonary fibrosis compared with participants without fi

118 Idiopathic pulmonary fibrosis comprised 34% with idiopathic acute e

119 mune cell type from patients with idiopathic pulmonary fibrosis could identify those at higher risk o

120 Patients with idiopathic pulmonary fibrosis could use nintedanib over the long-te

121 attenuation of its expression is integral to pulmonary fibrosis development.

122 s congenita, aplastic anemia, and idiopathic pulmonary fibrosis disrupt the binding between the prote

123 ients also primarily suffered morbidity from pulmonary fibrosis during follow-up.

124 Although relatives of patients with familial pulmonary fibrosis (FPF) are at an increased risk for in

125 nocyte counts in 45 patients with idiopathic pulmonary fibrosis from March 12, 2010, to March 10, 201

126 Secondary analysis distinguished idiopathic pulmonary fibrosis from non-idiopathic pulmonary fibrosi

127 to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, inc

128 trolled trials of IFN-gamma-1b in idiopathic pulmonary fibrosis (GIPF-001 [NCT00047645] and GIPF-007

129 roved anti-fibrotic drug to treat idiopathic pulmonary fibrosis, has been shown to ameliorate inflamm

130 athic pulmonary fibrosis from non-idiopathic pulmonary fibrosis ILD and used lung function to determi

131 immunodeficiency that leads to virus-induced pulmonary fibrosis.IMPORTANCE A variety of human rheumat

132 r coolers), CTD-ILD in 13.9%, and idiopathic pulmonary fibrosis in 13.7%.

133 plantation at index operation was idiopathic pulmonary fibrosis in 8 of 10 patients (1.2% of the 760

134 NJB2 also detected pulmonary fibrosis in a bleomycin-induced fibrosis model

135 Patients with idiopathic pulmonary fibrosis in a clinical trial of prednisone, az

136 broblast cells in vitro as well as to reduce pulmonary fibrosis in bleomycin-treated mice in vivo.

137 r animal modeling, we used a murine model of pulmonary fibrosis in conventional and germ-free mice.

138 ths were attributed to treatment: one due to pulmonary fibrosis in group B and one due to febrile neu

139 vival and resolved fibrosis in two models of pulmonary fibrosis in mice (intratracheal bleomycin and

140 miR-29 mimics prevent pulmonary fibrosis in mouse models but have not previous

141 gmental challenge model of bleomycin-induced pulmonary fibrosis in sheep to evaluate the remodelling

142 to-expiratory lung MRI for the assessment of pulmonary fibrosis in study participants with systemic s

143 h the anti-fibrotic drug pirfenidone reduced pulmonary fibrosis in this model.

144 g PBMC samples from patients with idiopathic pulmonary fibrosis in two independent cohorts (COMET and

145 capacity of these probes to detect and stage pulmonary fibrosis in vivo was assessed in a mouse model

146 ferentiation in lung fibroblasts ex vivo and pulmonary fibrosis in vivo.

147 ILD, including 456 patients with idiopathic pulmonary fibrosis (IPF) (men, 366; women, 90; median ag

148 l lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis.

149 such as the devastating diseases idiopathic pulmonary fibrosis (IPF) and scleroderma.

150 in a cohort of participants with idiopathic pulmonary fibrosis (IPF) and to evaluate the reproducibi

151 uted tomographic (CT) features of idiopathic pulmonary fibrosis (IPF) and to gain insight into the wa

152 Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in development.

153 hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent than those fo

154 Acute lung injury (ALI) and idiopathic pulmonary fibrosis (IPF) are severe lung diseases causin

155 tive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are two pathologically distinct

156 Patients with idiopathic pulmonary fibrosis (IPF) can experience life-threatening

157 Rationale: Idiopathic pulmonary fibrosis (IPF) causes considerable global morb

158 Fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) exhibited an increased abundanc

159 Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limite

160 large registries of patients with idiopathic pulmonary fibrosis (IPF) have been established.

161 tive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) have contrasting clinical and p

162 g biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could part

163 al telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere

164 adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (Evaluating

165 RATIONALE: Idiopathic pulmonary fibrosis (IPF) involves the accumulation of al

166 Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease

167 RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease

168 Idiopathic pulmonary fibrosis (IPF) is a chronic progressive inters

169 Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung d

170 Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung d

171 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and f

172 Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease chara

173 Idiopathic pulmonary fibrosis (IPF) is a deadly chronic lung diseas

174 Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increa

175 Idiopathic pulmonary fibrosis (IPF) is a devastating and fatal dise

176 Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating progressive di

177 Idiopathic pulmonary fibrosis (IPF) is a disease characterized by t

178 Idiopathic Pulmonary Fibrosis (IPF) is a disease with a devastating

179 Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year m

180 Idiopathic pulmonary fibrosis (IPF) is a fatal and incurable form o

181 Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown c

182 Idiopathic pulmonary fibrosis (IPF) is a fatal disease with a varia

183 Idiopathic pulmonary fibrosis (IPF) is a form of progressive inters

184 Idiopathic pulmonary fibrosis (IPF) is a lung parenchymal disease o

185 Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal inte

186 Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal inte

187 Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung

188 Idiopathic pulmonary fibrosis (IPF) is a progressive and heterogene

189 Idiopathic pulmonary fibrosis (IPF) is a progressive disease charac

190 Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a

191 Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial l

192 Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease w

193 Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorde

194 Idiopathic pulmonary fibrosis (IPF) is a rare and devastating chron

195 Idiopathic pulmonary fibrosis (IPF) is a severe form of lung fibros

196 Idiopathic pulmonary fibrosis (IPF) is characterized by altered epi

197 Idiopathic pulmonary fibrosis (IPF) is characterized by exuberant d

198 er, the role of these proteins in idiopathic pulmonary fibrosis (IPF) is not known.

199 risk among relatives of sporadic idiopathic pulmonary fibrosis (IPF) is not known.Objectives: To ide

200 Idiopathic pulmonary fibrosis (IPF) is progressive and rapidly fata

201 The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable.

202 expression was increased in human idiopathic pulmonary fibrosis (IPF) lung tissue.

203 Patients with idiopathic pulmonary fibrosis (IPF) often experience precipitous de

204 ung microbial community influence idiopathic pulmonary fibrosis (IPF) progression.

205 linical setting, the diagnosis of idiopathic pulmonary fibrosis (IPF) requires a pattern of usual int

206 Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a recombi

207 tress in AEC has been observed in idiopathic pulmonary fibrosis (IPF), a disease of aging.Objectives:

208 The progression and severity of idiopathic pulmonary fibrosis (IPF), a fatal and irreversible inter

209 ale: The relevance of hormones in idiopathic pulmonary fibrosis (IPF), a predominantly male lung dise

210 contribute to the development of Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal lung d

211 enic fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), have some of the worst prognos

212 ucity of effective treatments for idiopathic pulmonary fibrosis (IPF), new insights into the deleteri

213 In Idiopathic Pulmonary Fibrosis (IPF), there is unrelenting scarring

214 sis-free) donors or patients with idiopathic pulmonary fibrosis (IPF), which is a very aggressive fib

215 tic risk architecture observed in idiopathic pulmonary fibrosis (IPF), with key risk factors yet to b

216 onsidered a potential therapy for idiopathic pulmonary fibrosis (IPF).

217 le fibrotic conditions, including idiopathic pulmonary fibrosis (IPF).

218 al of inhaled CO in patients with idiopathic pulmonary fibrosis (IPF).

219 apeutic strategy in patients with idiopathic pulmonary fibrosis (IPF).

220 is pivotal to the development of idiopathic pulmonary fibrosis (IPF).

221 ies chronic lung diseases such as idiopathic pulmonary fibrosis (IPF).

222 the initiation and progression of idiopathic pulmonary fibrosis (IPF).

223 implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

224 ied rs2076295 in association with idiopathic pulmonary fibrosis (IPF).

225 se parenchymal diseases including idiopathic pulmonary fibrosis (IPF).

226 identify effective therapies for idiopathic pulmonary fibrosis (IPF).

227 and also in the fibrotic foci of idiopathic pulmonary fibrosis (IPF).

228 dysfunction to the development of idiopathic pulmonary fibrosis (IPF).Objectives: We sought to deciph

229 he highest genetic risk locus for idiopathic pulmonary fibrosis (IPF); however, the extent to which t

230 implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF); however, the repertoire of aut

231 Idiopathic pulmonary fibrosis is a deadly disease characterized by

232 Idiopathic pulmonary fibrosis is a fatal disease involving destruct

233 Idiopathic pulmonary fibrosis is a progressive scarring disease cha

234 Idiopathic pulmonary fibrosis is a prototype of chronic, progressiv

235 In humans and mice, pulmonary fibrosis is associated with up-regulation of s

236 fibroblasts, indicating that TERT's role in pulmonary fibrosis is cell type-specific.

237 however the role of vascular remodelling in pulmonary fibrosis is poorly understood.

238 A hallmark of idiopathic pulmonary fibrosis is the excess accumulation of extrace

239 have been implicated in the pathogenesis of pulmonary fibrosis, largely through their promotion of p

240 Idiopathic pulmonary fibrosis lung alveolar type II cells have incr

241 for increased AECII senescence in idiopathic pulmonary fibrosis lungs, suggesting potential clinical

242 onotype, and shift work) are associated with pulmonary fibrosis, making them risk factors.

243 Idiopathic pulmonary fibrosis may be associated with increased risk

244 own to be efficacious in a bleomycin-induced pulmonary fibrosis model in mice and in reducing extrace

245 In a bleomycin-induced mouse pulmonary fibrosis model, 5d from the series improved mo

246 cells (LR-MSCs) and in the lung tissues of a pulmonary fibrosis model.

247 idation of micro-computed tomography (CT) in pulmonary fibrosis models has not been performed.

248 In addition to the adverse effects caused by pulmonary fibrosis, most patients with IPF have associat

249 with PVOD (n = 19), PAH (n = 20), idiopathic pulmonary fibrosis (n = 13), and chronic obstructive pul

250 F (Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis) (n = 101) and an independent observa

251 available for adult patients with idiopathic pulmonary fibrosis, no clinical trials have been conduct

252 ke an early diagnosis of HP before extensive pulmonary fibrosis or restrictive lung disease has occur

253 ); chronic bronchitis (PAF, 13%); idiopathic pulmonary fibrosis (PAF, 26%); hypersensitivity pneumoni

254 iverse cell populations in the human lung to pulmonary fibrosis pathogenesis are poorly understood.

255 ations in lung microbiota critically promote pulmonary fibrosis pathogenesis.

256 In lung tissue from idiopathic pulmonary fibrosis patients, a strong up-regulation of u

257 o detect fibrotic lung disease in idiopathic pulmonary fibrosis patients.

258 an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.

259 al role for ER stress in the pathogenesis of pulmonary fibrosis (PF) and therapeutic potential of ER

260 osed first-degree relatives of patients with pulmonary fibrosis (PF) consented to participate in a sc

261 Pulmonary fibrosis (PF) is a major public health problem

262 the irradiated subjects most susceptible to pulmonary fibrosis (PF).

263 ective in a mouse model of bleomycin-induced pulmonary fibrosis (PF).

264 s, including dyskeratosis congenita (DC) and pulmonary fibrosis (PF).

265 ic obstructive pulmonary disease (COPD), and pulmonary fibrosis (PF).

266 ute to neomatrix formation and remodeling in pulmonary fibrosis (PF); TGF-beta, Factor Xa, thrombin,

267 tly a target for the treatment of idiopathic pulmonary fibrosis, recent times have seen the descripti

268 mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks 52, 72, an

269 ent-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and treatment-emer

270 ast differentiation/activation in idiopathic pulmonary fibrosis remain poorly understood.

271 mechanotransduction pathways associated with pulmonary fibrosis remains incomplete, recent progress h

272 The role of IL-17A in posttransplant pulmonary fibrosis remains incompletely understood.

273 nvironment and myofibroblast accumulation in pulmonary fibrosis remains unclear.

274 lasts have long been the focus of idiopathic pulmonary fibrosis research, the role of various subpopu

275 Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outc

276 Radiation-induced pulmonary fibrosis (RIPF) is a debilitating side effect

277 Radiation-induced pulmonary fibrosis (RTPF) is a progressive, serious cond

278 cal records of 7459 patients with idiopathic pulmonary fibrosis showed that patients with monocyte co

279 SPC-Tert cKO mice did not develop pulmonary fibrosis spontaneously up to 9 months of TERT

280 thdrawing life-sustaining therapies included pulmonary fibrosis, stroke, surrogate's desire to withdr

281 responses in a cellular model of idiopathic pulmonary fibrosis, supporting the potential of UCHL1 as

282 rds (EHR) of 45 068 patients with idiopathic pulmonary fibrosis, systemic sclerosis, hypertrophic car

283 igher in lungs from patients with idiopathic pulmonary fibrosis than in control individuals and were

284 es within individual cell populations during pulmonary fibrosis that are important for disease pathog

285 re syndromes manifest as familial idiopathic pulmonary fibrosis; they are the most common premature a

286 ses in preclinical disease models, including pulmonary fibrosis, thrombosis, and acute respiratory di

287 ibutes to the development and progression of pulmonary fibrosis through its regulation of ADORA2B exp

288 ), to determine if MARCKS inhibition reduces pulmonary fibrosis through the inactivation of PI3K/prot

289 of isolated fibroblasts in bleomycin-induced pulmonary fibrosis to be of endothelial origin.

290 to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] trial), including all patients rando

291 In a study of idiopathic pulmonary fibrosis, we reverse a paradoxical association

292 inase inhibitor, in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo

293 ed telomeres are risk factors for idiopathic pulmonary fibrosis, where repetitive injury to the alveo

294 Over time, these mice develop spontaneous pulmonary fibrosis, which is ameliorated by restoration

295 tivity pneumonitis are at risk of developing pulmonary fibrosis, which is associated with reduced sur

296 ing cells led to increased bleomycin-induced pulmonary fibrosis, which is mediated by increased expre

297 sease, but many patients develop progressive pulmonary fibrosis, which requires life-saving measures,

298 the Yale cohort, 15 patients with idiopathic pulmonary fibrosis (with five healthy controls) were cla

299 ree-quarters of individuals with SSc develop pulmonary fibrosis within 5 years, the main cause of SSc

300 ial, patients with a diagnosis of idiopathic pulmonary fibrosis within the past 3 years and forced vi